Filing Details

Accession Number:
0001209191-14-024136
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-04-01 16:29:48
Reporting Period:
2014-04-01
Filing Date:
2014-04-01
Accepted Time:
2014-04-01 16:29:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1273636 Applied Genetic Technologies Corp AGTC Biological Products, (No Disgnostic Substances) (2836) 593553710
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1291884 Medimmune Ventures, Inc. One Medimmune Way
Gaithersburg MD 20878
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-04-01 1,376,461 $0.00 1,376,461 No 4 C Direct
Common Stock Acquisiton 2014-04-01 75,735 $12.00 1,452,196 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1A Convertible Preferred Stock Disposition 2014-04-01 11,478,652 $0.00 690,678 $0.00
Common Stock Series B-1 Convertible Preferred Stock Disposition 2014-04-01 6,409,436 $0.00 183,126 $0.00
Common Stock Series B-2 Convertible Preferred Stock Disposition 2014-04-01 11,893,926 $0.00 339,826 $0.00
Common Stock Series B-3 Convertible Preferred Stock Disposition 2014-04-01 5,699,111 $0.00 162,831 $0.00
Series B-1 Convertible Preferred Stock Series B-1 Warrant (Right to Buy) Disposition 2014-04-01 416,361 $0.00 416,361 $0.13
Common Stock Common Stock Warrant (Right to Buy) Acquisiton 2014-04-01 11,896 $0.00 11,896 $4.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 2017-05-02 No 4 C Direct
11,896 2017-05-02 No 4 C Direct
Footnotes
  1. Each share of convertible preferred stock converted automatically into common stock upon the closing of the Issuer's initial public offering, and had no expiration date.
  2. Shares purchased in the Issuer's initial public offering at the initial public offering price of $12.00 per share.
  3. Not applicable.
  4. Each share of Series B-1 convertible preferred stock automatically converted into shares of common stock upon the closing of the Issuer's initial public offering on a 1-for-35 basis.
  5. Warrant was fully exercisable upon original issue.